Press Releases

Date Title and Summary
Toggle Summary Accuray CyberKnife® and TomoTherapy® Platforms Featured in More Than 55 Abstracts Presented at ESTRO 2023, Reinforcing Systems' Versatility, Efficiency and Effectiveness
Data Highlight Expanding Use of (Ultra) Hypofractionated Treatments, Benefits in Patient Care Made Possible by the Precision and Accuracy of Accuray Technologies SUNNYVALE, Calif. , May 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the
Toggle Summary Accuray Announces Suzanne Winter Selected as One of the Top 50 Healthcare Technology CEOs of 2023
SUNNYVALE, Calif. , June 15, 2023 /PRNewswire/ -- The global Accuray Incorporated (NASDAQ: ARAY) team is proud to announce that president and CEO Suzanne Winter has been recognized by The Healthcare Technology Report as one of the Top 50 Healthcare Technology CEOs of 2023.
Toggle Summary Accuray Incorporated Announces Its Addition to the Russell 2000® Index
SUNNYVALE, Calif. , June 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000 ® Index and the broad-market Russell 3000 ® Index, which will be effective
Toggle Summary Accuray to Report Fiscal Year-End 2023 Financial Results on August 9, 2023
SUNNYVALE, Calif. , July 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2023, ended June 30, 2023 , during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on August 9, 2023 .
Toggle Summary Accuray Reports Fourth Quarter and Fiscal 2023 Financial Results
8% Q4 revenue growth; Record shipments for FY23; Company issues guidance for FY24   MADISON, Wis. , Aug. 9, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2023, ended June 30, 2023 .       Fourth Quarter Fiscal 2023
Toggle Summary Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market
The Radixact System, with the addition of the VitalHold functionality, provides clinicians with unmatched choice of radiation treatment delivery options in one device Treatment delivery versatility offers opportunities for personalization and makes exceptional quality care possible for more breast
Toggle Summary Accuray to Host Investor Day at ASTRO on October 3, 2023
MADISON, Wis. , Sept. 14, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Tuesday, October 3, 2023 , in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.
Toggle Summary Accuray Opens New Global Training Center at Madison, WI Headquarters to Advance Radiotherapy Treatment Techniques Amid Growing Demand for Precision Cancer Care
Large classrooms and a hybrid, in-person/remote connection option will make it easier for more care providers to remain current on best practices and innovations in radiation therapy New center is part of the company's comprehensive education program which also includes on-site training, online
Toggle Summary Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
MADISON, Wis. , Oct. 2, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact ® System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO ( American
Toggle Summary Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration
MADISON, Wis. , Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA).

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.